Avacopan, a C5a receptor antagonist (C5aR) presents a new therapeutic option to improve outcomes in ANCA-associated vasculitis (AAV). Here we present a case report of a patient initially requiring kidney replacement therapy (KRT), where avacopan was added as an additional adjunctive therapeutic agent late in the treatment course.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/nep.14253 | DOI Listing |
Publication Analysis
Top Keywords
avacopan additional
8
anca-associated vasculitis
8
case report
8
additional therapeutic
4
therapeutic intervention
4
intervention promote
4
promote renal
4
renal recovery
4
recovery severe
4
severe anca-associated
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!